Fulcrum Therapeutics (FULC) Equity Ratio (2018 - 2026)
Fulcrum Therapeutics (FULC) has 9 years of Equity Ratio data on record, last reported at 0.96 in Q1 2026.
- On a quarterly basis, Equity Ratio rose 2.07% to 0.96 in Q1 2026 year-over-year; TTM through Mar 2026 was 0.96, a 2.07% increase, with the full-year FY2025 number at 0.95, up 2.21% from a year prior.
- Equity Ratio reached 0.96 in Q1 2026 per FULC's latest filing, up from 0.95 in the prior quarter.
- Over the last five years, Equity Ratio for FULC hit a ceiling of 0.96 in Q1 2026 and a floor of 0.82 in Q2 2022.
- A 5-year average of 0.91 and a median of 0.92 in 2024 define the central range for Equity Ratio.
- Peak YoY movement for Equity Ratio: decreased 2.51% in 2022, then grew 11.38% in 2023.
- Tracing FULC's Equity Ratio over 5 years: stood at 0.88 in 2022, then increased by 4.0% to 0.91 in 2023, then rose by 2.14% to 0.93 in 2024, then grew by 2.21% to 0.95 in 2025, then grew by 0.88% to 0.96 in 2026.
- Business Quant data shows Equity Ratio for FULC at 0.96 in Q1 2026, 0.95 in Q4 2025, and 0.92 in Q3 2025.